Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
The CUTR news page on Stock Titan aggregates historical and restructuring-related news for Cutera, Inc., a company focused on aesthetic and dermatology solutions within the surgical and medical instrument manufacturing sector. Company releases describe Cutera as a provider of energy-based medical aesthetic technologies for practitioners worldwide, with more than 25 years of activity in the medical aesthetics field.
News coverage for CUTR includes financial performance updates, such as quarterly results that break out product and service revenue, trends in capital systems sales, recurring revenue, and cash balances. These reports also describe cost restructuring programs, non-GAAP financial measures, and changes in operating expenses, offering insight into how the business has managed its cost structure and profitability goals over time.
Another major category of news involves capital structure and corporate transformation. In 2025, Cutera announced a pre-packaged Chapter 11 restructuring supported by existing lenders, with plans to reduce debt and raise new financing. Subsequent releases detailed its intention to voluntarily delist its common stock from the Nasdaq Global Select Market, suspend SEC reporting obligations through a planned Form 15 filing, and ultimately emerge from Chapter 11 as a private company backed by a consortium of investment firms.
Product and partnership announcements also appear in the CUTR news flow. Examples include updates on AviClear, described as a breakthrough technology for acne treatment, and truFlex® muscle stimulation, as well as an exclusive distribution agreement through Cutera KK to promote and distribute select SkinCeuticals® products to medical and physician-led clinics in Japan. Cutera has also highlighted collaborations such as its partnership with the Adaptive Training Foundation to provide truFlex treatments to adaptive athletes.
By reviewing the CUTR news archive, users can trace how Cutera communicated its business performance, product developments, partnerships, restructuring steps, and transition from a publicly traded company to a privately held entity. This makes the news page a useful resource for understanding the company’s historical trajectory and the events that shaped its capital structure and market presence.
Cutera (Nasdaq: CUTR) has appointed Jeryl 'Jeri' Hilleman to its Board of Directors, effective July 12, 2024. Hilleman brings over 30 years of experience in the healthcare industry, with a strong background in financial leadership, strategic planning, and corporate governance. She has served as CFO for multiple public healthcare companies, including Intersect ENT, Ocera Therapeutics, and Amyris. CEO Taylor Harris highlighted her expertise as critical for Cutera's growth and innovation, particularly with products like AviClear. Hilleman has also held significant governance roles, such as Chair of the Board at Omada Health and Audit Committee Chair at NovoCure, Minerva Neurosciences, and others.
Cutera announced an investor webinar to present AviClear, the first FDA-cleared energy device for treating inflammatory acne, on June 20, 2024, at 11 a.m. PDT. The session will cover clinical data, market potential, future studies, and user experiences. Key speakers include CEO Taylor Harris, CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, and dermatologists Dr. David J. Goldberg and Dr. Sonia Batra. The event will conclude with a live Q&A session for analysts and investors. Participants can join via the provided link or phone numbers. A replay will be available on Cutera’s website the next day.
Cutera, a leader in aesthetic and dermatology solutions, announced the granting of 44,500 non-qualified inducement stock options to six employees. Approved by the Compensation Committee of Cutera's Board of Directors, these options have an exercise price of $2.23, matching the closing price of Cutera's stock on the grant date, May 13, 2024.
The vesting schedule is as follows: 25% of the 29,500 stock options granted to five employees will vest annually, with an additional 1/48 vesting monthly, contingent on continued employment. For the remaining 15,000 stock options granted to one employee, 33% will vest annually with 1/36 vesting monthly, also subject to continued employment. These awards are part of Cutera's 2023 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Cutera, Inc. (Nasdaq: CUTR) reported Q1 2024 financial results with revenue of $38.8 million, a 29% decrease from the previous year. The company highlighted a strong sequential increase in AviClear revenue and the successful launch of xeo+. Gross profit was $12.4 million, operating expenses were $31.9 million, and cash equivalents were $105.4 million. Cutera reiterated its 2024 revenue guidance of $160-170 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
